Clinical trial · Research (general)← The news desk

✦ The Dispatch

Topical resiniferatoxin for the treatment of vestibulodynia: a prospective observational trial

A dispatch from PubMed — filed

Vestibulodynia is the most common subtype of vulvodynia and is characterized by persitent, contact-evoked pain localized to the vulvar vestibule. Increasing evidence supports a neuropathic pain mechanism in vestibulodynia, including vestibular hyperinnervation, neuroinflammation, and overexpression of the transient receptor potential vanilloid 1 receptor....

Clinical Takeaway

No actionable change for audiology practice — this trial addresses vulvodynia pain, which falls entirely outside the scope of audiology and vestibular audiology clinical care.

Why It Matters

While vestibulodynia involves the term 'vestibul-', this study is unrelated to the vestibular (balance) system and has no relevance to the audiology field.

Key Points
  1. 01Study evaluates topical resiniferatoxin, a potent TRPV1 agonist, for vestibulodynia.
  2. 02Vestibulodynia is a vulvar pain condition — not a vestibular (balance) disorder.
  3. 03Prospective observational design; no randomization or control group.
  4. 04This article is outside the scope of audiology, balance, or hearing science.
  5. 05Likely indexed in audiology feeds due to keyword overlap with 'vestibular' — not clinically relevant to audiologists.
Claims & Evidence

Topical resiniferatoxin is a candidate treatment for vestibulodynia (contact-evoked vulvar pain).

studypartially supported
Research metadata
PMID
42434379
DOI
10.1016/j.xagr.2026.100660.
Journal
AJOG Global Reports
Publication type
research_article
Evidence level
4
Population
Patients with vestibulodynia (contact-evoked vulvar vestibule pain)
Intervention
Topical resiniferatoxin applied to the vulvar vestibule

Primary outcomes

Pain reduction with contact stimulation at the vulvar vestibule; Safety and tolerability of topical resiniferatoxin

Related stories